Live Breaking News & Updates on Torl Biotherapeutics Llc

Stay updated with breaking news from Torl biotherapeutics llc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TORL BioTherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline

$158M Series B-2 Financing led by Deep Track Capital, with new participation from leading global biotechnology investors including RA Capital Management,. ....

Dave Licata , Vince Ruiz , Ribociclib Kisqali , Mark Alles , Palbociclib Ibrance , Dennis Slamon , Perceptive Xontogeny Venture Fund , Slamon Research Laboratory , Bristol Myers Squibb , Division Of Hematology Oncology , Roth Zabel , Crandon Law , David Geffen School Of Medicine , Deep Track Capital , Perceptive Advisors , Avidity Partners , Goldman Sachs Alternatives , Vertex Ventures , Moore Strategic Ventures , Blue Owl Healthcare Opportunities , Notch Ligand , Rebecca Luse , Deep Track , Board Member , Scientific Co Founder Dennis Slamon , Geffen School ,

TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Biologics

Co-founded by acclaimed oncologist Dennis Slamon, M.D., Ph.D., of University of California at Los Angeles (UCLA) and entrepreneur and CEO David Licata, as well. ....

Al Iskandariyah , David Licata , Lyell Immunopharma , John Glaspy , Martina Mcdermott , Amit Sinha , Neil Obrien , Mark Attanasio , Leonard Presta , Dennis Slamon , Sarah Larson , Brian Lawliss , Tom Boone , Ben Hoffstrom , Mark Alles , Lynn Seely , Head Of Life Sciences , Sachs Co , Crandon Law , Bristol Myers Squibb , Latham Watkins , Celgene Corporation , Crescent Capital Group , Goldman Sachs , University Of California At Los Angeles , Slamon Research Lab ,